Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cohort of Hepatitis B Research of Amsterdam (COBRA)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Public Health Service of Amsterdam.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
UMC Utrecht
Information provided by (Responsible Party):
S. Harkisoen, Public Health Service of Amsterdam
ClinicalTrials.gov Identifier:
NCT01462981
First received: October 28, 2011
Last updated: November 1, 2011
Last verified: November 2011

October 28, 2011
November 1, 2011
September 2011
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01462981 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Cohort of Hepatitis B Research of Amsterdam
Cohort of Hepatitis B Research of Amsterdam

Hepatitis B is a form of liver disease caused by a DNA-virus, called hepatitis B virus (HBV). Infection can result in an inflammation of the liver parenchyma with various clinical manifestations ranging from an asymptomatic course to jaundice. After contact with the virus the immunological response of the host determines the clinical outcome leading to either viral clearance or a chronic infection.

Although several factors are responsible for the development of chronic HBV-infection, one of the factors is a weak and transient CD8+ T-cell responses after HBV infection. In chronic hepatitis B, inflammation can lead to scarring which is the driving force to fibrosis and cirrhosis. Some immunological parameters, like a newly discovered subset of IL-17 producing T helper cells (Th17 cells), may influence the disease progression of HBV. In the cirrhotic patient, eventually there is an increased risk of hepatocellular carcinoma (HCC) leading to liver failure.

Recent literature in Asian patients with chronic hepatitis B showed that serum HBV viral load is a strong predictor for the development of cirrhosis, independent of hepatitis B e- antigen status and serum alanine transaminase level. It is unclear whether these results can be extrapolated to non-Asian (Caucasian and African) populations because of differences in host (HLA background) and viral (HBV genotype) factors.

The aim of this study is to elucidate the question whether historic HBV viral load is associated with the risk of HBV-related cirrhosis or mortality in a cohort of non-Asian individuals with chronic hepatitis B infection.

During one visit, the nurse will assess the quality of life of the included patients with the use of a health assessment questionnaire. This questionnaire is derived from a standardized questionnaire to assess the quality of life in patients, the SF-36. Participation will require a single visit to the outpatient clinic of Public Health Service. During this visit a short history and physical examination related to chronic liver disease will be performed. During the same visit a single venapunction and a single hepatic elastography (fibroscan) will be performed.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:

Serum, White cells

Non-Probability Sample

Women between 18 - 65 year in the study period with chronic hepatitis B who were HBsAg positive during pregnancy screening of which serum samples are stored at the Public Health Service.

Hepatitis B
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
172
July 2012
Not Provided

Inclusion Criteria:

  • HBsAg-positivity
  • Serum sample available from the screening programme at the Public Health Service
  • Still living and alive in Amsterdam or Diemen and address traceable by general practitioners or municipal authorities.
  • Non-Asian (both parents not born in Asia)
  • Between 18-65 years old
  • Capable of giving informed consent and capable of traveling to the Public Health Service

Exclusion Criteria:

  • Subjects coinfected with human immunodeficiency virus (HIV)
  • Subjects coinfected with hepatitis D virus (HDV)
  • Subjects coinfected with hepatitis C virus (HCV)
  • Subjects who are unable to come to the outpatient clinic
  • Subjects incapable to give informed consent due to legally incompetence
Female
18 Years to 65 Years
No
Contact: Soeradj Harkisoen, MD +31887556228 s.harkisoen@umcutrecht.nl
Netherlands
 
NCT01462981
COBRA
No
S. Harkisoen, Public Health Service of Amsterdam
Public Health Service of Amsterdam
UMC Utrecht
Principal Investigator: Andy IM Hoepelman, MD, PhD UMC Utrecht
Public Health Service of Amsterdam
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP